281 related articles for article (PubMed ID: 11106684)
1. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
Schiff R; Reddy P; Ahotupa M; Coronado-Heinsohn E; Grim M; Hilsenbeck SG; Lawrence R; Deneke S; Herrera R; Chamness GC; Fuqua SA; Brown PH; Osborne CK
J Natl Cancer Inst; 2000 Dec; 92(23):1926-34. PubMed ID: 11106684
[TBL] [Abstract][Full Text] [Related]
2. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
5. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
6. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.
Madeo A; Vinciguerra M; Lappano R; Galgani M; Gasperi-Campani A; Maggiolini M; Musti AM
Oncogene; 2010 Feb; 29(7):978-91. PubMed ID: 19935718
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.
Cui Y; Parra I; Zhang M; Hilsenbeck SG; Tsimelzon A; Furukawa T; Horii A; Zhang ZY; Nicholson RI; Fuqua SA
Cancer Res; 2006 Jun; 66(11):5950-9. PubMed ID: 16740736
[TBL] [Abstract][Full Text] [Related]
8. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
9. Regulation of human thioltransferase (hTTase) gene by AP-1 transcription factor under oxidative stress.
Krysan K; Lou MF
Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1876-83. PubMed ID: 12036993
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
[TBL] [Abstract][Full Text] [Related]
11. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
13. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
Gründker C; Schlotawa L; Viereck V; Emons G
Eur J Endocrinol; 2001 Nov; 145(5):651-8. PubMed ID: 11720885
[TBL] [Abstract][Full Text] [Related]
15. Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen.
Altundag K; Altundag O; Gunduz M; Arun B
Med Hypotheses; 2004; 63(5):823-6. PubMed ID: 15488654
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model.
Zhao Y; Xue Y; Oberley TD; Kiningham KK; Lin SM; Yen HC; Majima H; Hines J; St Clair D
Cancer Res; 2001 Aug; 61(16):6082-8. PubMed ID: 11507057
[TBL] [Abstract][Full Text] [Related]
18. RRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells.
Yu W; Simmons-Menchaca M; You H; Brown P; Birrer MJ; Sanders BG; Kline K
Mol Carcinog; 1998 Aug; 22(4):247-57. PubMed ID: 9726817
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
